"Dilute-and-inject" multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing

Analytical and Bioanalytical Chemistry

Volumn 407, Issue 18, 2015, Pages 5365-5379

  Görgens, Christian ^a   Guddat, Sven ^a   Orlovius, Anne Katrin ^a   Sigmund, Gerd ^a   Thomas, Andreas ^a   Thevis, Mario ^a   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Dilute and shoot; Doping analysis; Drug monitoring drug screening; HILIC; Human urine; Orbitrap

Indexed keywords

BODY FLUIDS; CHROMATOGRAPHY; DIRECT INJECTION; DRUG PRODUCTS; GLYCEROL; HYDROPHILICITY; LIQUIDS; MASS SPECTROMETRY; PATIENT MONITORING; SEPARATION; SPECTROMETRY; SPORTS;

DILUTE AND SHOOT; DOPING ANALYSIS; DRUG MONITORING; HILIC; HUMAN URINE; ORBITRAP;

LIQUID CHROMATOGRAPHY;

5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTIDIABETIC AGENT; CENTRAL STIMULANT AGENT; ETHYL GLUCURONIDE; GLUCURONIC ACID; GLYCEROL; INOSITOL PHOSPHATE; INOSITOL TRISPYROPHOSPHATE; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; RIBONUCLEOTIDE;

ANALOGS AND DERIVATIVES; CHEMICAL PHENOMENA; DEVICES; DOPING; EQUIPMENT DESIGN; FEMALE; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MALE; PROCEDURES; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE; VALIDATION STUDY;

AMINOIMIDAZOLE CARBOXAMIDE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; EQUIPMENT DESIGN; FEMALE; GLUCURONATES; GLYCEROL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPOGLYCEMIC AGENTS; INOSITOL PHOSPHATES; LIMIT OF DETECTION; MALE; MORPHINE DERIVATIVES; RIBONUCLEOTIDES; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84938096288     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-015-8699-x     Document Type: Article

References (45)

1. WADA (2014) The 2014 Prohibited List International Standard. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-Revised-2014-Prohibited-List-EN.PDF. Accessed 13 Nov 2014
2. Guddat S, Solymos E, Orlovius A, Thomas A, Sigmund G, Geyer H, Thevis M, Schänzer W (2011) High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test Anal 3:836-850
3. Thörngren JO, Östervall F, Garle M (2008) A high-throughput multicomponent screening method for diuretics, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC-MS/MS. J Mass Spectrom 43:980-992
4. Badoud F, Grata E, Perrenoud L, Avois L, Saugy M, Rudaz S, Veuthey JL (2009) Fast analysis of doping agents in urine by ultra-high pressure liquid chromatography-quadrupole time-of-flight mass spectrometry: I screening analysis. J Chromatogr A 1216:4423-4433
5. Alpert A (1990) Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J Chromatogr 499:177-196
6. Olsen BA, Pack BW (2013) Hydrophilic interaction chromatography - a guide for practitioners. Wiley, New Jersey
7. McCalley D (2010) Study of the selectivity, retention mechanisms and performance of alternative silica-based stationary phases for separation of ionised solutes in hydrophilic interaction chromatography. J Chromatogr A 1217:3408-3417
8. Heaton J, Gray N, Cowan DA, Plumb RS, Legido-Quigley C, Smith NW (2012) Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the separation of ephedrines. J Chromatogr A 1228:329-337
9. Gray N, Heaton J, Musenga A, Cowan DA, Plumb RS, Smith NW (2013) Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the quantification of ephedrines using medium-resolution accurate mass spectrometry. J Chromatogr A 1289:37-46
10. Marclay F, Saugy M (2010) Determination of nicotine and nicotine metabolites in urine by hydrophilic interaction chromatography-tandem mass spectrometry: potential use of smokeless tobacco products by ice hockey players. J Chromatogr A 48:7528-7538
11. Görgens C, Guddat S, Schänzer W, Thevis M (2014) Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Test Anal 6:1102-1107
12. Kolmonen M, Leinonen A, Kuuranne T, Pelander A, Ojanpera I (2010) Hydrophilic interaction liquid chromatography and accurate mass measurement for quantification and confirmation of morphine, codeine and their glucuronide conjugates in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 29:2959-2966
13. Mazzarino M, Fiacco I, de la Torre X, Botre F (2011) Screening and confirmation analysis of stimulants, narcotics and beta-adrenergic agents in human urine by hydrophilic interaction liquid chromatography coupled to mass spectrometry. J Chromatogr A 45:8156-8167
14. Orlovius AK, Guddat S, Parr MK, Kohler M, Gutschow M, Thevis M, Schänzer W (2009) Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESI-MS/MS. Drug Test Anal 1:568-575
15. Parr MK, Orlovius AK, Guddat S, Gütschow M, Thevis M, Schänzer W (2007) Sulfoconjugates of heavy volatile nitrogen containing doping substance for improved LC-MS/MS screening. Recent Advances in Doping Analysis, Sportverl Strauβ, Köln 15:97-102
16. WADA (2014) International Standard for Laboratories. Available at: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-ISL-2015-Final-v8.0-EN.pdf. Accessed: 13 Nov 2014
17. WADA (2014) Technical Document - TD2014MRPL. https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-TD2014MRPL-v1-Minimum-Required-Performance-Levels-EN.pdf. Accessed: 13 Nov 2014
18. Thevis M, Sigmund G, Geyer H, Schänzer W (2010) Stimulants and doping in sport. Endocrinol Metab Clin North Am 39:89-105
19. Dring LG, Smith RL, Williams RT (1970) Metabolic fate of amphetamine in Man and other species. Biochem J 116:425-435
20. Hayakawa K, Miyoshi Y, Kurimoto H, Matsushima Y, Takayama N, Tanaka S, Miyazaki M (1993) Simultaneous determination of methamphetamine and its metabolites in the urine samples of abusers by high-performance liquid-chromatography with chemiluminescence detection. Biol Pharm Bull 16:817-821
21. Shimosato K, Tomita M, Ijiri I (1986) Urinary-excretion of P-hydroxylated methamphetamine metabolites in man. Arch Toxicol 59:135-140
22. Shima N, Kamata HT, Katagi M, Tsuchihashi H (2006) Urinary excretion of the main metabolites of methamphetamine, including p-hydroxymethamphetamine-sulfate and p-hydroxymethamphetamine-glucuronide, in humans and rats. Xenobiotica 36:259-267
23. Shima N, Tsutsumi H, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H (2006) Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users' urine. J Chromatogr B Anal Technol Biomed Life Sci 830:64-70
24. Hengstmann JH, Weyand U, Dengler HJ (1975) Physiological disposition of etilefrine in man. Eur J Clin Pharmacol 9:179-187
25. Kauert G, Angermann C, Lex H, Spes C (1988) Clinical pharmacokinetics after a single oral dose of oxilofrine. Int J Clin Pharmacol Res 8:307-314
26. Verho M, Malerczyk V, Kauert G, Lorenz H (1988) Dose linearity and relative bioavailability testing of oxilofrine, a sympathomimetic drug, in healthy-volunteers. Int J Clin Pharmacol Res 8:211-215
27. Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1974) The physiological disposition of p-octopamine in man. Naunyn-Schmiedeberg's Arch Pharmacol 283:93-106
28. WADA (2014) Technical Document - TD2014DL. https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-TD2014DL-v1-Decision-Limits-for-the-Quantification-of-Threshold-Substances-EN.pdf. Accessed: 13 Nov 2014
29. Thevis M, Guddat S, Flenker U, Schänzer W (2008) Quantitative analysis of urinary glycerol levels for doping control purposes using gas-mass spectrometry. Eur J Mass Spectrom 14:117-125
30. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405-415
31. Thevis M, Thomas A, Kohler M, Beuck S, Schänzer W (2009) Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J Mass Spectrom 44:442-460
32. Barre L, Richardson C, Hirshman MF, Brozinick J, Fiering S, Kemp BE, Goodyear LJ, Witters LA (2007) Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation. Am J Physiol Endocrinol Metab 292:E802-E811
33. Thomas A, Beuck S, Eickhoff JC, Guddat S, Krug O, Kamber M, Schänzer W, Thevis M (2010) Quantification of urinary AICAR concentrations as a matter of doping controls. Anal Bioanal Chem 396:2899-2908
34. Piper T, Thomas A, Baume N, Sobolevsky T, Saugy M, Rodchenkov G, Schänzer W, Thevis M (2014) Determination of 13C/12C ratios of endogenous urinary 5-amino-imidazole-4-carboxamide 1β-D-ribofuranoside (AICAR). Rapid Commun Mass Spectrom 28:1194-1202
35. Falk O, Palonek E, Björkhem I (1988) Effect of ethanol on the ratio between testosterone and epitestosterone in urine. Clin Chem 34:1462-1464
36. Geyer H, Mareck U, Haenelt N, Schänzer W (2009) Atypical steroid profiles in connection with ethanol findings in urine. Recent advances in doping analysis, sportverl. Strauβ, Köln 17:261-264
37. Große J, Anielski P, Sachs H, Thieme D (2009) Ethylglucuronide as a potential marker for alcohol-induced elevation of urinary testosterone/epitestosterone ratios. Drug Test Analysis 1:526-530
38. Görgens C, Guddat S, Thomas A, Geyer H, Schänzer W (2011) Identification and quantitative determination of long-term alcohol markers ethylglucuronide and ethylsulfate in human urine by LC-MS/MS in doping control analysis. Recent advances in doping analysis, sportverl. Strauβ, Köln 19:209-312
39. Thieme D, Große J, Keller GM (2011) Urinary concentrations of ethyl glucuronide and ethyl sulfate as thresholds to determine potential ethanol-induced alteration of steroid profiles. Drug Test Analysis 3:851-856
40. Hasselström J, Säwe J (1993) Morphine pharmacokinetics and metabolism in humans: enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24:344-354
41. Osborne R, Joel S, Trew D, Slevin M (1990) Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12-19
42. Kilpatrick GJ, Smith TW (2005) Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25:521-44
43. Fylaktakidou KC, Lehn JM, Greferath RC, Nicolau C (2005) Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett 15:1605-1608
44. Duarte CD, Greferath R, Nicolau C, Lehn JM (2010) Myo-inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chem Bio Chem 11:2543-2548
45. Suth J (2004) Efaproxiral: a novel radiation sensitiser. Expert Opin Investig Drugs 13:543-550